AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00575718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires
Description: Same components of HC+NRT as well as the PS/SRS enhancement.The research team will provide education about scheduled reduced smoking either in person or over the phone. Purpose of the training session, will be audio taped, to prepare participants for daily PDA use over the dur of the scheduled-reduced smoking intervention. Training will demonstrate use of PDA and simulate common technical and procedural issues that might arise during the intervention (e.g., forgetting to record a cigarette or wake time; repeating a day's schedule if needed, prior to the quit date). The simulation will reflect anticipated problems and those identified by users of the PDA. A study helpline number and instructional manual will be provided. A member of the research staff will contact the study participants, once the reduced smoking schedule has begun, to check that the patient understands the schedule and that the PDA is working properly. Estimate patient training with the PDA will require 30 minutes.
Study NCT03400176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: Experimental
Study NCT03400176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Approved medication
Study NCT04335981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FT-CC and Swallow Exercises
Description: Once daily treatment with FT Plus with investigational connectivity software and standard of care swallow exercises.
Study NCT04335981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Swallow Exercises
Description: Standard of care swallow exercises.
Study NCT02738879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg, oral, once daily for 30 weeks
Study NCT02738879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to sitagliptin
Description: Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
Study NCT02738879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).
Study NCT02738879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).
Study NCT02738879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin XR
Description: At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.
Study NCT02738879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.
Study NCT02738879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
Study NCT02738879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
Study NCT00451893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein operation with a heavy-weight mesh
Description: Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2
Study NCT00451893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein operation with a light-weight mesh
Description: Johnson\&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
Study NCT02078453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Dental treatment of all dental needs present in the children related or not to the dental caries.
Study NCT02078453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental treatment
Description: Dental treatment of all dental needs present in the children related or not to the dental caries.
Study NCT04697420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: Thoracic paravertebral block is a technique in which , the local anesthetic agent is injected in the paravertebral space to anesthetise the spinal nerves after emerging from the vertebral canal in order to provide analgesia in the thoracic and upper abdominal area .
Study NCT04697420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: Transversus abdominis plane block is a technique is mostly done under ultrasound guidance to identify the transversus plane between the internal oblique muscle and the transverses abdominis muscle , the space in which the neurovascular supply of the anterior abdominal wall is present , and hence the injection of local anesthetic agent in this space results in anesthesia of the anterolateral aspect of the abdominal wall.
Study NCT00399412 — intervention group
Intervention type: DEVICE
Intervention: subcutaneous ICD
Study NCT03527810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy Without Interrogation of Hiatus
Description: Weight-loss procedure to reduce the stomach.
Study NCT03527810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy With Interrogation of Hiatus
Description: Weight-loss procedure to reduce the stomach with hiatal repair.
Study NCT01814293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handheld humidifier
Description: Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) \& control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
Study NCT00751049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
Study NCT00751049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhXA41
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
Study NCT03555565 — intervention group
Intervention type: DRUG
Intervention: Alogliptin and Metformin hydrochloride
Description: Alogliptin and Metformin hydrochloride combination tablets
Study NCT04986410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA, CT-MPI, CT-FFR, SPECT-MPI
Description: Subjects undergo CCTA, CT-MPI, CT-FFR or SPECT-MPI
Study NCT00759460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: 12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
Study NCT00759460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
Study NCT04870099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doing What Matters in Times of Stress: An Illustrated Guide
Description: From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances.
Study NCT02251145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir low dose
Study NCT02251145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir high dose
Study NCT02251145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir low dose
Study NCT02251145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high dose
Study NCT02251145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Study NCT00214149 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: breast brachytherapy to 34 Gy
Study NCT04010903 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: assessment of biomarkers of insulin resistance
Description: blood and urine sample collection for assays of BCAAs
Study NCT04081090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain HQ Cognitive Modules
Description: Online personalized cognitive therapy modules to address and improve neuroplasticity.
Study NCT04081090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain HQ Cognitive Modules
Description: Online personalized cognitive therapy modules to address and improve neuroplasticity.
Study NCT01504607 — intervention group
Intervention type: PROCEDURE
Intervention: Congenital Cataract Surgery
Description: Congenital cataract surgery with IOL implantation
Study NCT02983149 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Double lumen tube
Description: Use an double lumen tube to achieve one lung ventilation in thoracic surgeries
Study NCT02983149 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fuji blocker
Description: Use the Fuji blocker to achieve one lung ventilation in thoracic surgeries
Study NCT02983149 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EZ blocker
Description: Use the EZ blocker to achieve one lung ventilation in thoracic surgeries
Study NCT00438100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
Study NCT00438100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
Study NCT01893060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
Study NCT01893060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
Study NCT01893060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pluronic Cream
Description: Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place
Study NCT01893060 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
Study NCT03104062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microbubble Contrasted Echocardiography
Description: Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography
Study NCT03104062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Platelet Aggregability
Description: Obtained using Multiplate Analyzer
Study NCT03104062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Laboratory
Description: it will be collected at patients arrival, Reative C-Protein, BNP, CK-mass, Troponine, interleukine-6, Creatinine.
Study NCT00818467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tanning spray
Description: using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks
Study NCT00818467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: receiving 40mJ UV-B phototherapy three times a week for four weeks
Study NCT00154778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol, UFT,Leucovorin
Study NCT04374162 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PEEP
Description: different PEEP set on the anesthetic machine
Study NCT04374162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: different PEEP set on the anesthetic machine
Study NCT03144271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
Study NCT03144271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo will be administered subcutaneously (s.c. under the skin)
Study NCT01751334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty
Description: Mobile Bearing Total knee Arthroplasty
Study NCT01751334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Fixed Total Knee Arthroplasty
Study NCT03909750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Description: Close syringe microcannula harvesting subdermal fat and perivascular stem/stromal cells
Study NCT03909750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AD-cSVF
Description: Isolation of AD-cSVF
Study NCT03909750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline IV
Description: Normal Saline IV containing AD-cSVF
Study NCT00985998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab and chemotherapy
Description: The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4\~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4\~6cycles).~the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12\~18 weeks).
Study NCT01092039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactoferrin, L-Glutamine and beta-glucans
Description: Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.
Study NCT01092039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactoferrin, L-Glutamine and beta-glucans
Description: Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.
Study NCT01092039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.
Study NCT02554058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling and Mechanical stimulation
Description: Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
Study NCT04794374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation will consists of physiotherapist-guided exercises. Exercises will be designed by physiotherapists for COVID-19 survivors using the current guidelines. Exercise brochure will be prepared and will be sent to participants. Repetitions and sets of exercises will be modified according to the patients.
Study NCT02089958 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic incisional hernia repair
Description: Standardized laparoscopic incisional hernia repair with mesh
Study NCT02553499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1248
Description: IV infusion
Study NCT02553499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study NCT04188431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Is usually commercialized as dexamethasone phosphate as solution for injection
Study NCT04188431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: prepared in the same intravenous volume to mimic experimental arm
Study NCT05565040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumcision in concealed penis
Description: comparison of three surgical techniques (as described in the arms) in the management of concealed penis in pediatrics
Study NCT04597541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.
Study NCT01819428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV120101 (Poziotinib)
Description: NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
Study NCT01572493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-15 (10 DAYS)
Description: Continuous infusion of recombinant human Interleukin-15 (rh IL-15) intravenous (IV) for first 10 days of each cycle
Study NCT01572493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-15 (5 DAYS)
Description: Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle
Study NCT02312362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined sclerotomy ab interno and phaco
Study NCT02312362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification with IOL implantation
Study NCT03156608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novii ECG/EKG System
Description: External fetal heart rate monitoring
Study NCT03156608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External fetal heart rate monitoring
Description: External fetal heart rate monitoring
Study NCT00076063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452)
Description: experimental vaccine
Study NCT00076063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIPO-5
Description: experimental vaccine
Study NCT03845582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK-001 oral capsule
Description: Daily administration for 24 months
Study NCT03845582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Daily administration for 24 months
Study NCT03689543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER beta agonist
Description: We propose to evaluate the efficacy of a selective estrogen receptor (ER) beta agonist (Lilly Compound LY500307) to prevent estradiol withdrawal-induced mood symptoms. The effects of estradiol primarily occur through activation of two receptor subtypes, often with opposing outcomes: estrogen receptor (ER) alpha, and ER beta. We focus on ER beta because the beta estrogen receptor is reported to mediate the effects of estradiol on the serotonergic system and mediate the antidepressant-like effects of estradiol in the forced-swim test.
Study NCT03689543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER beta agonist
Description: We propose to evaluate the efficacy of a selective estrogen receptor (ER) beta agonist (Lilly Compound LY500307) to prevent estradiol withdrawal-induced mood symptoms. The effects of estradiol primarily occur through activation of two receptor subtypes, often with opposing outcomes: estrogen receptor (ER) alpha, and ER beta. We focus on ER beta because the beta estrogen receptor is reported to mediate the effects of estradiol on the serotonergic system and mediate the antidepressant-like effects of estradiol in the forced-swim test.
Study NCT03689543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01863316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I gel
Study NCT01863316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme
Study NCT02879656 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-operative treatment
Description: conservative treatment with 5 weeks cast immobilization
Study NCT02879656 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: operative treatment
Description: surgery with volar locking plate with modified Henry's volar approach
Study NCT02184585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence A
Description: FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
Study NCT02184585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence B
Description: FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
Study NCT02184585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence C
Description: Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).